Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study

NCT07680699 is registered in ClinicalTrials.gov with AC Camargo Cancer Center as lead sponsor.

NCT NCT07680699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study
Lead sponsor
AC Camargo Cancer Center
Phase
Observational
Overall status
Recruiting
Start date
April 23, 2025
Completion date
May 31, 2027
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma